EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nasopharyngeal Microbial Signatures Associated with Anti-VEGF Therapeutic Outcomes in Exudative Age-Related Macular Degeneration: A Pilot Study

Dzastina Cebatoriene, Akvile Bruzaite iD, Alvita Vilkeviciute-Petraite iD, Dalia Zaliuniene, Rokas Lukosevicius iD, Jurgita Skieceviciene, Juozas Kupcinskas, Rasa Liutkeviciene iD

International Journal of Molecular Sciences · 28.10.2026 · 27 (21) · 9673

DOI: 10.3390/ijms27219673 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.10.2026. Verfasst von Dzastina Cebatoriene und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor A, Microbiota, Macular Degeneration, Nasopharynx. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Lithuania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Exudative age-related macular degeneration (AMD) is driven by choroidal angiogenesis, and the response to anti-vascular endothelial growth factor (anti-VEGF) therapy varies between patients. In this pilot study, we investigated whether the pretreatment nasopharyngeal microbiota differs between patients with exudative AMD and controls and whether it is associated with treatment response. Nasopharyngeal swabs were analysed by 16S rRNA gene (V3–V4) amplicon sequencing; after removal of host-derived, chloroplast and contaminant sequences and rarefaction, 55 samples (25 patients and 30 controls) were retained. Treatment response was assessed six months after starting therapy. Community composition was compared using permutational multivariate analysis of variance (PERMANOVA) adjusted for age, sex and statin use. Alpha and beta diversity did not differ between patients and controls (Shannon index, p = 0.892; PERMANOVA, p = 0.067). Pretreatment community composition differed between 19 responders and five non-responders (Bray–Curtis R2 = 0.057, p = 0.015; weighted UniFrac R2 = 0.143, p = 0.006), and non-responders had lower diversity (observed ASVs, p = 0.004). Non-responders had a higher relative abundance of Corynebacterium (median 71% vs. 19%; p = 0.009), which did not remain significant after correction for all genera tested. Pretreatment nasopharyngeal microbiota composition was associated with the response to anti-VEGF therapy but not with AMD status. These preliminary findings require confirmation in larger, independent cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor AMicrobiotaMacular DegenerationNasopharynxAngiogenesis InhibitorsHumansPilot ProjectsFemaleMaleAgedRNA, Ribosomal, 16SAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

16S rRNA sequencingCorynebacteriumbevacizumabmacular neovascularizationranibizumabupper respiratory tract microbiome

Substanzen

Vascular Endothelial Growth Factor ARNA, Ribosomal, 16SAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
  • Laboratory of Ophthalmology, Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.
  • Department of Ophthalmology, Medical Academy, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.
  • Laboratory of Clinical and Molecular Gastroenterology, Institute for Digestive Research, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
  • Department of Gastroenterology, Academy of Medicine, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.

ORCID-Profile: Akvile Bruzaite, Alvita Vilkeviciute-Petraite, Rokas Lukosevicius, Rasa Liutkeviciene

Förderung

  • Research Council of Lithuania

Zitieren

APA

Cebatoriene, D., Bruzaite, A., Vilkeviciute-Petraite, A., Zaliuniene, D., Lukosevicius, R., Skieceviciene, J., Kupcinskas, J., & Liutkeviciene, R. (2026). Nasopharyngeal Microbial Signatures Associated with Anti-VEGF Therapeutic Outcomes in Exudative Age-Related Macular Degeneration: A Pilot Study. International Journal of Molecular Sciences, 27(21), 9673. https://doi.org/10.3390/ijms27219673

Vancouver

Cebatoriene D, Bruzaite A, Vilkeviciute-Petraite A, Zaliuniene D, Lukosevicius R, Skieceviciene J, et al. Nasopharyngeal Microbial Signatures Associated with Anti-VEGF Therapeutic Outcomes in Exudative Age-Related Macular Degeneration: A Pilot Study. International Journal of Molecular Sciences. 2026;27(21):9673. doi:10.3390/ijms27219673

BibTeX
@article{Cebatoriene2026,
  author = {Cebatoriene, Dzastina and Bruzaite, Akvile and Vilkeviciute-Petraite, Alvita and Zaliuniene, Dalia and Lukosevicius, Rokas and Skieceviciene, Jurgita and Kupcinskas, Juozas and Liutkeviciene, Rasa},
  title = {Nasopharyngeal Microbial Signatures Associated with Anti-VEGF Therapeutic Outcomes in Exudative Age-Related Macular Degeneration: A Pilot Study},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {21},
  pages = {9673},
  doi = {10.3390/ijms27219673}
}
Kostenlos starten →